Pfizer this week revealed that it has increased the price of Paxlovid, its antiviral drug used to reduce the risk of getting sick from COVID-19 in those who are most vulnerable. His new price arrives around $1.400, more than double the roughly $530 the US government paid during the pandemic.
Pfizer CEO Albert Bourla had told investors earlier this week that the company would raise the price of Paxlovid as it moves from government distribution to the commercial market later this year.
But then he did not announce the new price. The company revealed the more than doubling in a letter to pharmacies and clinics on Wednesday. The Wall Street Journal was the first to report the price of $1.390.
A Pfizer spokesperson told the Journal that "Pricing for Paxlovid is based on the value it provides to patients, and healthcare systems because of its important role in reducing hospitalizations and deaths related to COVID-19."
A cost-effectiveness analysis last year pegged Paxlovid's value at between $563 and $906 per treatment, according to the nonprofit drug price watchdog The Institute for Clinical and Economic Review.
George is still wondering what he is doing here….
Let them put them where they know, we don't want them...
We were fed up with their Inflation.